NCT01471665View on ClinicalTrials.gov

GSK2190915 Neutrophilic Asthma Study

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Asthma
Interventions
DRUG

GSK2190915 100mg

GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.

DRUG

Placebo

Placebo will be administered once daily for up to 16 days.

Trial Locations (1)

G12 0YN

GSK Investigational Site, Glasgow

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01471665 - GSK2190915 Neutrophilic Asthma Study | Biotech Hunter | Biotech Hunter